r
c
l
e
n
f
keyword
pseudotyp
viru
vaccin
serolog
zoonot
viru
b
r
c
global
world
economi
accompani
increas
intern
travel
chang
climat
alter
human
behaviour
demograph
lead
emerg
differ
viral
diseas
mani
highli
pathogen
henc
consid
great
public
anim
health
import
undertak
basic
research
therapeut
develop
mani
virus
requir
handl
highli
train
staff
facil
readili
avail
major
global
r
commun
order
circumv
enhanc
biosafeti
requir
develop
nonpathogen
replicationdefect
pseudotyp
virus
effect
establish
solut
permit
studi
mani
aspect
viru
biolog
low
contain
biosafeti
level
bsl
laboratori
spectr
unfold
ebola
crisi
time
confer
second
organis
viral
pseudotyp
unit
wwwviralpseudotypeunitinfo
discuss
recent
advanc
pseudotyp
technolog
revolution
studi
import
human
anim
pathogen
human
avian
influenza
virus
rabieslyssavirus
hiv
marburg
ebola
virus
key
topic
address
confer
includ
exploit
pseudotyp
serolog
serosurveil
immunogen
test
current
nextgener
vaccin
new
pseudotyp
assay
format
multiplex
kit
develop
first
pseudotypefocus
euroscicon
confer
organis
viral
pseudotyp
unit
recent
review
see
front
matter
http
dx
altern
wildtyp
virus
wide
use
tool
offer
rang
benefit
research
diagnost
therapeut
treatment
option
pseudotyp
virus
pv
replicationdefect
viral
particl
form
structur
enzymat
core
one
viru
envelop
glycoprotein
anoth
flexibl
option
littl
associ
risk
professor
robin
weiss
univers
colleg
london
uk
review
field
retroviru
pseudotyp
oncolog
vaccinolog
keynot
address
retrovirus
vesicular
stomat
viru
vsv
abil
assembl
envelop
lead
develop
retrovir
vector
bear
vsv
envelop
glycoprotein
retrovir
vector
commonli
use
deliv
gene
choic
within
pv
gene
transfer
gene
therapi
applic
addit
vsv
envelop
highli
pathogen
rna
virus
pseudotyp
onto
retrovir
vector
benefit
highcontain
necessari
import
exampl
applic
technolog
present
prof
weiss
includ
use
rabi
viru
pseudotyp
studi
neutralis
antibodi
sera
vaccin
subject
use
retrovir
pseudotyp
haemagglutinin
ha
select
crossneutralis
influenza
viru
mab
direct
stalk
region
chair
address
dr
nigel
temperton
joint
director
viral
pseudotyp
unit
univers
kent
uk
introduc
influenza
viru
pseudotyp
resourc
group
establish
last
year
remit
establish
pandem
prepared
resourc
consist
retrovir
vector
pseudotyp
influenza
viru
subtyp
wild
bird
reservoir
combin
wide
array
report
deploy
multitud
resourc
set
field
industri
tabl
ha
pseudotyp
employ
serosurveil
immunogen
test
basic
tool
studi
viru
entri
produc
via
transfect
cell
hpai
strain
belong
subtyp
season
lpai
strain
plasmid
hiv
mlv
gagpol
envelop
glycoprotein
report
gene
fig
addit
contain
singl
basic
amino
acid
cleavag
site
proteaseexpress
plasmid
requir
h
h
posttransfect
supernat
harvest
filter
titrat
onto
suscept
target
cell
line
mdck
upon
viru
emerg
pseudotyp
platform
offer
abil
rapidli
commenc
serosurveil
antigen
characteris
studi
low
contain
level
thu
assist
vaccin
antivir
develop
particularli
advantag
studi
highli
pathogen
zoonot
virus
pose
signific
public
health
threat
main
research
interest
dr
edward
wright
univers
westminst
uk
spoke
pseudotyp
emerg
zoonot
virus
lyssaviru
filoviru
henipaviru
genera
tabl
provid
viral
candid
bud
structur
gag
pol
enzymat
protein
express
singl
plasmid
lack
packag
signal
envelop
env
gene
express
plasmid
promot
pro
specif
envelop
report
gene
express
plasmid
incorpor
packag
signal
flank
long
tandem
repeat
ltr
along
upstream
promot
detail
influenza
b
strain
pseudotyp
viral
pseudotyp
unit
univers
kent
strain
present
subtyp
order
year
isol
strain
highlight
red
includ
document
antigen
genet
characterist
zoonot
influenza
virus
develop
candid
vaccin
virus
pandem
prepared
septemb
host
cell
plasma
membran
two
envelop
glycoprotein
toxic
produc
cell
requir
addit
proteas
process
express
pseudotyp
platform
describ
temperton
wright
prove
highli
success
approach
five
ebolaviru
speci
gener
dr
wright
group
within
short
timefram
includ
makona
variant
guinea
implic
current
outbreak
ebolaviru
pseudotyp
current
implement
pseudotyp
viru
neutralis
assay
pvna
fig
assist
clinic
trial
vaccin
eboz
collabor
jenner
institut
univers
oxford
serolog
studi
vital
assess
neutralis
abil
antibodi
target
envelop
glycoprotein
assist
track
viru
spread
provid
import
public
health
epidemiolog
data
pv
form
robust
wildtyp
viru
altern
serolog
assay
dr
wright
discuss
proven
flexibl
sensit
studi
undertak
neutralis
assay
rang
report
gene
incorpor
within
pv
core
offer
varieti
cost
time
benefit
choic
quantit
qualit
readout
work
gener
lyssaviru
pv
test
antirabi
viru
neutralis
respons
found
result
correl
sensit
valid
wildtyp
viru
assay
report
stabil
pv
maintain
high
viral
titr
coldchain
storag
follow
freezethaw
cycl
offer
signific
advantag
wildtyp
viru
titr
drop
rapidli
permit
use
countri
less
reliabl
infrastructur
recent
flexibl
substanti
studi
produc
pv
express
chimer
envelop
glycoprotein
pseudotyp
vsv
envelop
glycoprotein
vsvg
highli
effici
rel
low
titr
achiev
rabi
cv
strain
challeng
viru
standard
pv
shown
rescu
construct
chimer
glycoprotein
cytoplasm
domain
rabi
viru
g
protein
switch
vsvg
dr
wright
group
follow
approach
engin
envelop
glycoprotein
arcticlik
rabi
viru
success
increas
previous
unwork
titr
allow
serolog
studi
perform
assess
previous
unknown
efficaci
current
vaccin
antivir
rabi
viru
subset
valu
focus
meet
intradisciplinari
collabor
commun
highlight
project
deriv
euroscicon
pv
meet
dr
giada
mattiuzzo
nibsc
uk
work
valid
altern
neutralis
assay
test
biolog
potenc
postexposur
prophylaxi
pep
rabi
immunoglobulin
rig
rabi
signific
public
health
burden
result
almost
death
per
year
million
peopl
receiv
pep
worldwid
administr
rig
import
compon
pep
provid
passiv
immunis
inhibit
viral
spread
suffici
activ
immun
achiev
via
vaccin
current
rig
deriv
immunis
human
plasma
donor
must
undergo
potenc
test
establish
european
pharmacopoeia
monograph
releas
european
market
rapid
fluoresc
focu
inhibit
test
rffit
biolog
potenc
assay
outlin
within
monograph
cellbas
neutralis
assay
must
undertaken
bsl
due
use
wildtyp
rabi
viru
name
laboratori
strain
challeng
viru
standard
dr
mattiuzzo
evalu
pvna
allevi
need
high
contain
requir
bsl
use
pv
express
glycoprotein
initi
construct
dr
wright
increas
safeti
access
offer
pvna
dr
mattiuzzo
outlin
express
luciferas
report
gene
offer
object
result
readout
current
rffit
requir
immunostain
cell
count
fluoresc
via
microscopi
field
per
dilut
prepar
signific
disadvantag
comparison
autom
luminesc
measur
use
luciferas
report
gene
similar
current
rffit
pvna
evalu
biolog
potenc
rig
base
abil
inhibit
target
cell
infect
potenc
test
assess
rig
parallel
world
health
organis
intern
standard
antirabi
immunoglobulin
dr
mattiuzzo
evalu
commerci
rig
sampl
use
pvna
shown
calibr
produc
similar
potenc
obtain
via
rffit
manufactur
independ
institut
produc
rig
batch
releas
intellectu
properti
issu
surround
commerci
use
report
plasmid
construct
pcsflw
need
resolv
pvna
repres
promis
altern
system
potenc
test
rig
collabor
valid
studi
dr
mattiuzzo
present
pvna
inclus
european
pharmacopoeia
monograph
rig
increas
safeti
access
potenc
test
dr
temperton
spoke
advantag
use
pv
season
influenza
viru
serolog
pvna
ideal
influenza
viru
strain
difficult
propag
cultur
like
recent
virus
viru
cultur
necessari
serolog
assay
entir
synthet
also
pvna
may
prove
easier
standardis
reli
erythrocyt
exhibit
signific
variabl
haemagglutinationinhibit
hi
assay
ha
influenza
viru
antigen
incorpor
pseudotyp
particl
antibodi
sole
direct
protein
measur
assay
thu
use
tool
dissect
respons
observ
use
wildtyp
viru
microneutralis
mn
assay
short
assay
format
essenti
antiha
respons
measur
long
assay
format
antiha
antina
respons
measur
due
virus
undertak
one
cycl
replic
neutralis
infect
releas
viru
dr
temperton
propos
pseudotyp
assay
use
adjunct
emafda
approv
serolog
assay
hi
singl
radial
hemolysi
srh
compar
routin
run
hi
assay
serumspar
antigenspar
biosaf
straightforward
scaleup
larg
sampl
size
multiplex
format
interassay
variabl
like
reduc
multiplex
format
adapt
differ
subtyp
pair
measur
antibodi
respons
two
virus
belong
differ
respiratori
viru
group
influenza
virus
conjunct
sar
mer
coronavirus
tabl
show
current
influenza
viru
strain
constitut
vpu
influenza
resourc
use
pv
altern
current
gold
standard
demonstr
professor
emanuel
montomoli
vismederi
siena
itali
present
comparison
pseudotyp
versu
tradit
neutralis
advantag
futur
perspect
standpoint
small
medium
enterpris
sme
involv
immunogen
test
influenza
viru
vaccin
pharmaceut
industri
mn
assay
titrat
function
antibodi
current
gold
standard
confirm
howev
difficult
employ
screen
larg
sampl
set
highcontain
facil
requir
pandem
strain
mn
detect
antibodi
bind
around
globular
head
block
viru
attach
entri
addit
detect
crossreact
antibodi
bind
stem
region
ha
contrast
hi
srh
correl
protect
establish
pvna
yet
titr
use
indic
seroposit
season
strain
pvna
suitabl
screen
larg
sampl
set
exhibit
good
correl
mn
season
pandem
strain
influenza
viru
current
pvna
wide
establish
remain
unvalid
clinic
usag
cdc
mn
protocol
involv
pretreat
sera
receptordestroy
enzym
result
obtain
measur
viral
infect
via
nucleoprotein
np
elisa
readout
perform
mn
includ
evalu
cytopath
effect
well
subject
interpret
perform
ha
assay
supernat
use
either
turkey
guinea
pig
erythrocyt
possibl
influenc
erythrocyt
type
mn
titr
mn
exhibit
poor
reproduc
laboratori
use
differ
protocol
fold
assay
would
benefit
valid
standardis
viru
input
growth
kinet
differ
serum
treatment
dilut
pvna
requir
treatment
sera
readout
perform
simpl
measur
transduc
cell
use
gfp
luciferas
extrapol
pvna
titr
correspond
mn
titr
calcul
seroprotect
endpoint
novarti
monoval
subunit
vaccin
studi
studi
shown
pvna
use
serum
plasma
na
pseudotyp
mismatch
ha
use
measur
na
antibodi
enzymelink
lectin
assay
stuart
mather
viral
pseudotyp
unit
univers
kent
uk
describ
feasibl
lyophilis
pseudotyp
lentivirus
bear
array
heterolog
glycoprotein
could
realist
includ
serolog
kit
flexibl
report
gene
encapsul
retrovir
core
well
abil
multiplex
viru
neutralis
assay
pseudotyp
bear
differ
envelop
report
gene
significantli
increas
util
broaden
scope
employ
assay
worldwid
especi
resourc
limit
region
howev
current
major
obstacl
dissemin
pv
necess
maintain
coldchain
condit
transport
longterm
storag
mr
mather
present
candid
influenza
rabi
marburg
pseudotyp
lentivirus
could
withstand
lyophilis
presenc
sucrosepb
cryoprotect
mediumterm
storag
temperatur
c
reconstitut
either
water
dmem
cultur
medium
whilst
retain
hightitr
pseudotyp
infect
enabl
exploit
downstream
serolog
assay
durabl
pseudotyp
lentivirus
confirm
mr
mather
research
allud
possibl
incorpor
serolog
assay
kit
could
global
distribut
fraction
current
cost
dri
ice
shipment
store
number
week
regardless
ambient
temperatur
climat
keynot
address
prof
weiss
spoke
pv
employ
search
vaccin
current
clone
envelop
gene
clade
circul
recombin
form
crf
avail
pv
invalu
reagent
develop
vaccin
commun
neutralis
antibodi
target
envelop
glycoprotein
whilst
potent
broadli
neutralis
human
mab
isol
map
use
pv
immunogen
screen
complex
elicit
weak
narrow
neutralis
polyclon
antibodi
weiss
lab
sought
address
issu
use
llama
elicit
broadli
neutralis
mab
camelida
classic
nonclass
igg
produc
heavi
chain
antibodi
reformat
vhh
singl
chain
antibodi
vhh
exploit
hiv
rabi
viru
influenza
viru
rsv
exhibit
potent
neutralis
profil
pv
strain
neutralis
llama
vhh
two
vhh
combin
strain
neutralis
studi
bind
vhh
pocket
found
depend
bind
site
integr
excit
translat
applic
vhh
usag
vagin
immunoprophylaxi
hiv
transmiss
lend
applic
stabl
buffer
gel
refold
heat
c
vhh
formul
gel
silicon
addit
secret
commens
lactobacilli
vagina
current
macaqu
vagin
gel
trial
progress
vhh
join
via
glyser
gs
linker
peptid
form
bival
vhh
potenc
dramat
increas
heterobihead
vhh
potent
bival
vhh
mper
potent
dr
simon
scott
joint
director
viral
pseudotyp
unit
univers
kent
uk
outlin
definit
applic
pv
serolog
gene
therapi
perspect
emphasis
versatil
pv
due
array
core
envelop
protein
employ
platform
dr
scott
present
research
dissect
vaccinolog
equin
influenza
viru
use
lentivir
pseudotyp
firstli
pvna
correl
well
establish
srh
assay
quantifi
neutralis
antibodi
respons
panel
vaccin
equin
sera
also
equin
influenza
viru
pseudotyp
utilis
studi
vaccin
breakdown
hors
introduc
specif
point
mutat
put
antigen
epitop
ha
repres
pre
postoutbreak
influenza
viru
strain
gaug
contribut
vaccin
escap
via
reduct
neutralis
antibodi
recognit
pvna
assay
dr
scott
ongo
project
also
discuss
includ
product
pv
display
envelop
seal
canin
influenza
viru
isol
inher
complex
gener
pv
japanes
enceph
west
nile
flavivirus
discuss
bud
intern
endoplasm
reticulum
er
mean
prm
e
envelop
protein
assembl
emb
er
membran
oppos
plasma
membran
case
altern
core
pseudotyp
foami
viru
vector
could
offer
feasibl
solut
influenza
associ
ill
signific
global
healthcar
burden
annual
epidem
result
million
case
sever
ill
approxim
associ
death
licens
influenza
viru
vaccin
suboptim
protect
popul
cohort
risk
influenza
associ
diseaseold
adult
young
children
protect
role
heterosubtyp
influenza
virusspecif
tcell
demonstr
human
challeng
studi
intern
influenza
viru
antigen
np
matrix
protein
induc
strong
tcell
specif
respons
build
dr
teresa
lamb
jenner
institut
oxford
uk
spoke
group
work
ration
design
vaccin
name
mvanp
modifi
vaccinia
viru
ankara
vector
express
influenza
viru
antigen
np
boost
tcell
direct
influenza
viru
respons
younger
older
adult
phase
iia
challeng
symptom
less
pronounc
vaccine
compar
control
adjuv
properti
poxvirus
previous
report
dr
lamb
group
demonstr
mvanp
augment
humor
immun
follow
season
influenza
viru
vaccin
preclin
clinic
studi
preclin
studi
use
pvna
luciferas
express
lentivir
pseudotyp
produc
viral
pseudotyp
unit
kent
evalu
function
capac
antibodi
allow
assess
antibodi
direct
ha
head
stem
region
addit
studi
look
safeti
immunogen
second
viral
vector
boost
influenza
virusspecif
tcell
respons
replicationdefici
chimpanze
adenoviru
vector
express
influenza
viru
antigen
np
establish
dr
ann
moor
univers
colleg
cork
ireland
present
find
immun
respons
induc
dissolv
microneedl
dmn
patch
place
skin
differ
induc
needleandsyring
base
parenter
immunis
ucc
research
team
develop
transcutan
immunis
system
base
microneedl
array
term
immupatch
microneedl
micronscal
needl
penetr
skin
creat
conduit
vaccin
administr
dr
moor
previous
demonstr
deliveri
liquid
coat
vaccin
silicon
microneedl
induc
potent
protect
immun
respons
mice
meet
dr
moor
exhibit
novel
dmn
patch
technolog
vaccin
embed
microneedl
dissolv
upon
contact
moistur
skin
therebi
elimin
requir
vaccin
reconstitut
retain
vaccin
potenc
longterm
stabil
season
influenza
viru
vaccin
immupatch
store
c
rel
humid
present
thu
demonstr
potenti
technolog
overcom
coldchain
obstacl
strong
focu
develop
influenza
viru
vaccin
induc
broadli
neutralis
antibodi
respons
present
immunogen
influenza
viru
vaccin
deliv
dmn
patch
intramuscular
rout
mice
pig
discuss
dr
moor
group
investig
breadth
humor
respons
induc
intramuscular
patchbas
immunis
use
pvna
demonstr
signific
differ
differ
administr
rout
use
respect
antibodi
recognit
heterosubtyp
influenza
viru
ha
protein
present
season
influenza
viru
vaccin
preclin
result
therefor
suggest
addit
enhanc
stabil
immupatch
may
also
clinic
util
respect
broaden
humor
immun
critic
featur
reduc
potenti
pathogen
escap
common
factor
requir
success
gene
therapi
genet
vaccin
applic
dissimilar
includ
uptak
vector
appropri
cell
vector
entri
host
either
evad
host
immun
defenc
gene
therapi
result
immunostimul
vaccin
among
viral
vector
system
gene
therapi
applic
adenoviru
lentiviru
adenoassoci
viru
aav
common
dr
taki
athanasopoulo
univers
wolverhampton
uk
spoke
work
use
vector
system
pseudotyp
gene
therapeut
genet
vaccin
target
hivaid
adenoviru
natur
isol
plu
speciesspecif
chad
capsid
base
modif
variant
wide
test
vaccin
vehicl
previou
studi
group
use
common
serotyp
andor
altern
serotyp
effect
skin
vaccin
vehicl
adenoviru
vector
express
effect
target
langerhan
cell
genet
vaccin
cohort
lentivir
pseudotyp
also
test
professor
dickson
lab
vandermuelen
unpublish
uk
gener
multiepitop
vlpenvelop
vaccin
lastli
aav
vector
pseudotyp
tool
wide
use
field
gene
therapi
could
applic
target
hiv
via
secret
immunoadhesin
use
muscl
platform
express
immunoprophylaxi
protect
humanis
mice
mucos
hiv
transmiss
studi
target
chemokin
coreceptor
use
gene
edit
technolog
lesson
learn
field
gene
therapi
duchenn
muscular
dystrophi
dmd
appli
design
effect
immunotherapeut
hiv
vice
versa
phase
clinic
trial
use
poorli
design
constitut
express
minidystrophin
cassett
packag
pseudotyp
characteris
high
seropreval
human
popul
result
dystrophin
immunityvaccin
type
outcom
contrast
aav
pseudotyp
capsid
mutant
express
tissuespeci
specif
gene
interest
canin
microdystrophin
administ
dog
model
dmd
may
far
effect
gene
therapeut
approach
yet
poor
directli
administ
vaccin
vehicl
sinc
may
escap
immunesurveil
nevertheless
dr
athanasopoulo
discuss
poor
vaccin
candid
could
use
effect
gene
edit
tool
includ
express
talen
znf
dr
athanasopoulo
group
project
system
vectoris
aav
lentiviru
target
vivo
ex
vivo
cell
receptor
pathway
hivaid
infecti
diseas
dr
yasuhiro
takeuchi
univers
colleg
london
uk
exhibit
research
hivbas
pseudotyp
particl
two
distinct
approach
stabl
continu
product
sugar
antigen
display
pseudotyp
surfac
utilis
lentivir
vector
gene
therapi
purpos
held
back
rel
pauciti
packag
cell
line
pcl
consist
produc
safe
effect
lentivir
vector
lv
batch
whilst
adher
strict
current
good
manufactur
practic
cgmp
guidelin
dr
takeuchi
provid
detail
group
work
construct
cgmpcompliant
pcl
stabli
produc
selfinactiv
lv
winpac
base
upon
origin
constitut
lv
pcl
name
star
prefer
safeti
characterist
gener
winpac
cell
activ
genom
loci
cell
initi
loxptag
expand
exploit
empti
pv
immunogen
transduct
gammaretrovir
vector
isol
stabl
highlyexpress
clone
introduct
codonoptimis
hiv
gagpol
cassett
via
cre
recombinasemedi
cassett
exchang
rmce
fig
plasmid
encod
hiv
rev
rdpro
endogen
retroviru
envelop
protein
gfpexpress
lv
stabli
transfect
winpac
cell
rdpropseudotyp
lentivirus
stabli
produc
winpac
pcl
abl
effici
transduc
human
tcell
cell
thu
offer
promis
winpac
utilis
product
lv
could
deliv
therapeut
gene
treatment
xscid
bcell
malign
addit
dr
takeuchi
outlin
display
number
clinicallyrelev
carbohydr
antigen
hiv
pseudotyp
use
virusbas
assay
instanc
gal
gal
termin
carbohydr
express
mammal
human
lack
function
galactosyltransferas
gene
therefor
human
rais
strong
antibodi
respons
caus
acut
reject
xenotransplant
similarli
human
produc
nglycolylneuramin
acid
due
inact
requir
hydroxylas
mean
burn
victim
receiv
pigskin
elicit
high
antibodi
level
product
gfpharbour
hiv
pv
display
saccharid
antigen
viru
envelop
utilis
assay
viru
pull
assay
work
monitor
amount
viru
pull
target
antibodi
magnet
bead
use
sybr
green
realtim
pcrenhanc
revers
transcriptas
assay
quantif
antibodi
respons
rais
oligosaccharid
use
novel
approach
could
significantli
improv
understand
reject
mediat
antigen
organ
tissu
xenotransplant
meet
demonstr
pv
repres
highlyflex
platform
applic
mani
domain
includ
serolog
serosurveil
antibodi
standard
develop
vaccin
immunogen
test
gene
therapyvaccin
amongst
other
mani
viral
pathogen
public
anim
health
import
wreak
havoc
across
globe
today
highcontain
zoonot
thu
access
wildtyp
viru
sever
constrain
biosecur
reason
synthet
natur
pseudotyp
system
render
invalu
studi
virus
appar
meet
pv
becom
wide
use
entrench
within
r
landscap
multipl
sector
benefit
pv
highlight
throughout
meet
togeth
recommend
toward
futur
develop
tabl
heighten
anticip
wait
see
use
put
next
instal
confer
vaccin
pseudotyp
vlp
product
standardis
vaccin
greenwich
octob
http
wwwregonlineco
ukbuildersitedefaultaspx
